Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Nylander M, Frossing S, Clausen HV, Kistorp C, Faber J, Skouby SO (2017) Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial
DOI: 10.1105/tpc.11.6.1153 36
In small proof-of-concept phase 2 randomized controlled trials (RCTs) in patients with biopsy-confirmed MASH, liraglutide at 1.8 mg/day for 48 weeks (201), semaglutide at 0.4 mg/day for 72 weeks (202), and tirzepatide at 15 mg/week for 52 weeks (203) have been reported to achieve placebo-corrected percentages of participants meeting the criteria for resolution of MASH without worsening fibrosis by 30% (P = 0.019), 42% (P 10%) may lead to diabetes remission (237)
doi:10.1002/14651858.CD009891.pub2
US$ 21.20
US$ 28.04
US$ 20.51
US$ 23.31
US$ 27.69
US$ 28.50
